We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Saliva Test Fast Tracks Heart Attack Diagnosis

By LabMedica International staff writers
Posted on 07 Sep 2020
Print article
Image: A test tube contains saliva that can be tested for the heart attack biomarker cardiac troponin (Photo courtesy of karenfoleyphoto).
Image: A test tube contains saliva that can be tested for the heart attack biomarker cardiac troponin (Photo courtesy of karenfoleyphoto).
Heart attacks need urgent diagnosis, followed by treatment to restore blood flow to blocked arteries. Diagnosis is based on symptoms (such as chest pain), an electrocardiogram (ECG) and a blood test for cardiac troponin, a protein released into the blood when the heart muscle is injured.

A saliva test could fast track heart attack diagnosis, according to a preliminary study. The innovative technique requires patients to spit into a tube and provides results in 10 minutes, compared to at least one hour for the standard blood test and saliva collection is a non-invasive.

Medical scientists at the Soroka University Medical Centre (Be’er Sheva, Israel) examined if cardiac troponin could be detected in the saliva of patients with heart muscle injury. Saliva samples underwent a unique processing procedure to remove highly abundant proteins. The processing procedure is called Saliva High Abundant Proteins Effective Depletion (SHAPED). A total of 32 patients with heart muscle injury (i.e. they had a positive cardiac troponin blood test) and 13 healthy volunteers were requested to provide saliva samples by spitting into a collecting tube. Then, half of each sample was processed, and the other half remained in its natural state. They then tested the processed and unprocessed saliva samples for cardiac troponin.

The investigators compared the results from the saliva samples (processed and unprocessed) with the blood samples. There was strong agreement between the blood findings and the processed saliva, but not saliva in its natural state. Most of the processed saliva samples tested were positive for troponin, compared to just 6% of the unprocessed saliva. Of the 25 patients with myocardial injury whose samples had advanced processing, 21 were confirmed positive for MI by both methods (sensitivity, 84.0%). Among healthy participants, no cardiac troponin was detected in the processed and unprocessed saliva samples.

Roi Westreich, MD, A Cardiologist and lead author of the study, said, “Since no test has been developed for use on saliva, we had to use commercially available tests intended for whole blood, plasma, or serum, and adjust them for saliva examination. This early work shows the presence of cardiac troponin in the saliva of patients with myocardial injury. Further studies are needed to determine how long troponin stays in the saliva after a heart attack. In addition, we need to know how many patients would erroneously be diagnosed with heart attack and how many cases would be missed.” The study was presented at the digital European Society of Cardiology 2020 congress held August 29 to September 1, 2020 via Sophia Antipolis, France.

Related Links:
Soroka University Medical Centre

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.